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Evaluation and Diagnostic Potential of Serum Ghrelin in Feline
Hypersomatotropism and Diabetes Mellitus
K.B. Jensen, Y. Forcada, D.B. Church, and S.J.M. Niessen
Background: Ghrelin is a growth hormone secretagogue. It is a potent regulator of energy homeostasis. Ghrelin concen-
tration is down-regulated in humans with hypersomatotropism (HS) and increases after successful treatment. Additionally,
ghrelin secretion seems impaired in human diabetes mellitus (DM).
Hypothesis: Serum ghrelin concentration is down-regulated in cats with HS-induced DM (HSDM) compared to healthy
control cats or cats with DM unrelated to HS and increases after radiotherapy.
Animals: Cats with DM (n = 20) and with HSDM (n = 32), 13 of which underwent radiotherapy (RT-group); age-
matched controls (n = 20).
Methods: Retrospective cross-sectional study. Analytical performance of a serum total ghrelin ELISA was assessed and
validated for use in cats. Differences in serum ghrelin, fructosamine, IGF-1 and insulin were evaluated.
Results: Ghrelin was significantly higher (P < .001) in control cats (mean  SD: 12.9  6.8 ng/mL) compared to HSDM-
(7.9  3.3 ng/mL) and DM-cats (6.7  2.3 ng/mL), although not different between the HSDM- and DM-cats. After RT
ghrelin increased significantly (P = .003) in HSDM-cats undergoing RT (from 6.6  1.9 ng/mL to 9.0  2.2 ng/mL) and the
after RT ghrelin concentrations of HSDM cats were no longer significantly different from the serum ghrelin concentration of
control cats. Serum IGF-1 did not significantly change in HSDM-cats after RT, despite significant decreases in fructosamine
and insulin dose.
Conclusion and Clinical Importance: Ghrelin appears suppressed in cats with DM and HSDM, although increases after
RT in HSDM, suggesting possible presence of a direct or indirect negative feedback system between growth hormone and
ghrelin. Serum ghrelin might therefore represent a marker of treatment effect.
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Feline hypersomatotropism (HS) is caused by a func-tional somatotropic adenoma or hyperplasia of the
pars distalis of the anterior pituitary gland resulting in
excessive growth hormone (GH) secretion.1 The diabe-
togenic effect of excess GH leads to diabetes mellitus
(DM), which is often the initial clinical presentation. In
the long run, the anabolic effects of GH-induced insu-
lin-like growth factor 1 (IGF-1) can lead to characteris-
tic physical changes, including soft tissue growth
resulting in the syndrome of acromegaly.1,2 The diagno-
sis of HS remains difficult, since no single test can pro-
vide a satisfactory definitive diagnosis. Additionally,
feline GH assays are not widely available commercially
and therefore have currently limited value in a clinical
setting despite acceptable sensitivity and specificity.5
Although the usefulness of serum IGF-1 as a diagnostic
marker for HS has been documented, false negative
and false positive results do occur and positive results
therefore require confirmation of a pituitary lesion with
advanced imaging; this is expensive and requires heavy
sedation or general anesthesia.4,6,7 Refinement of exist-
ing endocrine testing or development of alternative tests
for HS is therefore desirable. Easier, more reliable and
accessible diagnostics would facilitate earlier diagnosis
of HS as the inciting cause of DM in cats and facilitate
more rapid and appropriate treatment, increasing the
chance for diabetic remission. Alternative endocrine
tests might help establish the true efficacy of HS treat-
ment, which is especially relevant after radiotherapy
(after RT), since IGF-1 seems an unreliable marker for
this purpose, thus rendering many cats vulnerable to
potentially serious iatrogenic hypoglycemia.7,8
Although ghrelin was first identified as an endoge-
nous ligand for the GH secretagogue receptor, it is now
mostly known as an orexigenic peptide.9 Little is known
about the role of ghrelin in endogenous GH-secretion
during normal physiological conditions. Nevertheless,
From the Department of Clinical Sciences and Services, The Royal
Veterinary College, University of London, Hatfield, Hertfordshire UK
(Jensen, Forcada, Church, Niessen).
This research was performed at the Department of Clinical Sci-
ences and Services of The Royal Veterinary College.
Previously presented as part of an abstract at the 22nd European
College of Veterinary Internal Medicine-Companion Animals
(ECVIM-CA) Congress in Maastricht, September 6–8, 2012, The
Netherlands and published as an abstract in Journal of Veterinary
Internal Medicine 2012; 26(1).
Corresponding author: S.J.M. Niessen, Department of Veterinary
Clinical Sciences, Royal Veterinary College, Hatfield, Hertforshire
AL97TA, UK; e-mail: sniessen@rvc.ac.uk.
Submitted January 13, 2014; Revised October 28, 2014;
Accepted December 2, 2014.
Copyright © 2015 by the American College of Veterinary Internal
Medicine
DOI: 10.1111/jvim.12536
Abbreviations:
BSH British shorthair
CT computed tomography
DLH domestic longhair
DM diabetes mellitus
DSH domestic shorthair
ELISA enzyme-linked immunosorbent assay
GH growth hormone
Gy gray
HS hypersomatotropism
IGF-1 insulin growth factor 1
RIA radioimmunoassay
RT radiotherapy
rt room temperature
J Vet Intern Med 2015;29:14–20
studies in humans have shown that serum ghrelin con-
centrations are lower when HS is present, indicating
existence of a possible direct or indirect negative feed-
back system between GH and ghrelin.10,11 Additionally,
serum ghrelin rises after successful surgical removal of a
somatotrophinoma.10,12 Ghrelin has also been shown to
suppress insulin release and modify insulin sensitivity,
processes at the heart of the etiopathogenesis of type 2
DM, which currently remains incompletely under-
stood.13,14 Screening for dysregulation of ghrelin secre-
tion and correlations between ghrelin and the level of
glycemic control in uncomplicated or primary feline
DM (non-HS-induced feline DM) is therefore of addi-
tional interest, alongside its use as a control group for
HS-induced diabetic cats.
The aim of this study was to validate a serum ghrelin
ELISA for use in cats and to evaluate serum ghrelin in
feline HS and DM, specifically comparing serum ghrelin
in cats with HS-induced DM (HSDM), cats with
uncomplicated or primary DM (DM) and healthy cats,
as well as assessing the effect of radiotherapy (RT) on
circulating ghrelin concentration in HSDM-cats, com-
pared to the traditionally used serum IGF-1.
Material and Methods
Sample Recruitment
Residual serum was collected from samples from three groups
of cats: healthy cats (control-cats, N = 20), insulin treated cats
with uncomplicated or primary DM (DM-cats, N = 20) and cats
with HSDM (HSDM-cats, N = 32). All groups were age-matched;
DM-cats and control-cats were weight-matched. From a subgroup
(N = 13) of the HSDM-cats samples were also collected before
and after RT. All cats were starved for 8–10 hours before sam-
pling and all samples were taken before insulin administration.
Serum was separated through centrifugation, separated into aliqu-
ots and stored at 80°C within 1 hour of collection. Fructos-
amine, IGF-1 and ghrelin were measured in samples obtained at
the same time. Cats were categorized into the DM-group on the
basis of clinical signs (polyuria, polydipsia, and polyphagia), clini-
copathological findings consistent with DM (persistent hyperglyce-
mia and concurrent glycosuria, serum fructosamine concentration
>350 lmol/L, serum total IGF-1 concentration <700 ng/mL) and
modest insulin requirements with adequate diabetic control at time
of sampling and during follow-up (<1.5 IU/kg/injection). All cats
had been diagnosed, and administered exogenous insulin, a mini-
mum of 1 month before sample collection and follow-up data
(minimum of 6 months) were available for all cats. Cats were cate-
gorized into the HSDM-group on the basis of a diagnosis of DM
(criteria above excluding insulin requirements condition), a serum
total IGF-1 concentration >900 ng/mL (all determined by the
same RIA, Cambridge Specialist Laboratories Services, Cam-
bridge, UK) and demonstration of a pituitary lesion on brain
imaging studies (contrast-enhanced computed tomography [CT] or
magnetic resonance imaging [MRI]). In 13 HSDM cats additional
serum samples were obtained after completion of hypo-or hyper-
fractionated RT (12 cats: total dose of 37 gyay (Gy) in five once-
weekly fractions and 1 cat: total dose of 37 (Gy) in ten escalating
fractions delivered three times weekly; median collection time after
RT completion: 12 months; range 3–32 months, 25–75% percentile
5–14 months). The upper limit for the IGF-1 RIA assay used
was 2000 ng/mL and values above this limit were therefore
reported as 2,000 ng/mL. Residual sample from 20 age-matched
cats undergoing a routine health screen were used as healthy con-
trols; all had normal serum biochemistry (including glucose), uri-
nalysis, and serum total thyroxine results during this health screen.
Ethical approval for sample collection had been obtained previ-
ously from the Royal Veterinary College local ethical committee.
Ghrelin Assay Protocol
A competitive enzyme-linked immunosorbent assay (ELISA) kit
for Rat/Mouse Ghrelina,b was validated for this study. The use of
this particular assay for the measurement of ghrelin in cats has
previously been reported and is based on the similarities between
rat and cat ghrelin.15,16 The assay was conducted in accordance
with the manufacturer’s instructions. In brief, 15 lL of serum was
added to 135 lL of assay buffer, vortexed and 50 lL transferred
into wells primed with secondary antibody, followed by addition
of primary antibody and biotinylated peptide. The plate was incu-
bated for 2 hours at room temperature (rt) during orbital shaking
(300–400 rpm) and then thoroughly washed using assay buffer.
Streptavidin-peroxidase enzyme was added and left for 1 hours at
rt during orbital shaking followed by washing and addition of
3,30,5,50-tetramethylbenzidine (TMB) substrate; the reaction was
stopped after 1 hour of incubation by adding hydrochloric acid
(0.5N). The color intensity was measured immediately at 450 nm.c
A standard curve was generated through dilution of provided stan-
dard recombinant rat/mouse ghrelin (concentrations: 0.01, 0.1, 1.0,
10, and 100 ng/mL). Based on duplicate measurements, concentra-
tions were determined by multiplying the concentrations obtained
from intra-polation of the standard curve data points with the
dilution factor (1 : 10).
Ghrelin Assay—Analytical Performance
The precision of the ELISA was evaluated by calculating intra-
and inter-assay coefficients of variation (CV). For determination
of the intra-assay CV, three serum samples from cats in the con-
trol- and HSDM-group with a range of ghrelin concentrations
were each determined ten times during one ELISA run. For deter-
mination of the interassay CV, three serum samples from cats
from the same groups with a range of ghrelin concentrations were
determined in duplicate in three ELISA runs. Separately frozen
aliquots from the same residual sample were used to exclude inter-
ference from freeze–thaw cycles. CVs were expressed as a percent-
age and calculated by dividing the standard deviation (SD) by the
mean of the measurements.
In the absence of purified feline ghrelin, the accuracy of the
assay was evaluated indirectly by linearity under dilution and
recovery studies. For linearity under dilution, serum from two of
the control cats was serially diluted (2-fold) using the provided
assay buffer. Additionally, to exclude matrix effects, two samples
with high and low concentrations of ghrelin were mixed at differ-
ent ratios to create percentage dilutions of 100%, 75%, 50%,
25%, and 0%. Feline ghrelin recovery was expressed as a percent-
age ([measured/expected concentration] 9 100) for each dilution.17
The limit of detection (LoD) was determined on the basis of 18
repeat measurements of the zero standard and defined as the mean
plus three standard deviations.
Statistical Analysis
In order to evaluate sample matrix effects, linearity under dilu-
tion was assessed by ordinary linear regression analysis comparing
measured and expected ghrelin concentrations.
Data were evaluated for normality using the Kolmogorov-Smir-
nov test and normally distributed data were described using mean
and SD, whereas non-normally distributed data were described
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using median and range. Comparison of variables between DM,
HSDM and control was performed using one-way ANOVA fol-
lowed by posthoc Tukey’s multiple comparison test. Comparison
between two groups were performed using unpaired or paired
t-test for unpaired or paired normally distributed data and the
Mann-Whitney U-test or paired-sample Wilcoxon signed rank test
for unpaired or paired non-normally distributed data. Addition-
ally, Bonferroni posthoc correction was performed for multiple
t-test comparisons between paired observations (before and after
RT) and controls.
Pearson (parametric) or Spearman (nonparametric) correlation
analyses were used to assess for a correlation between changes in
ghrelin and insulin dose, IGF-1 and fructosamine before and after
RT and for a correlation between ghrelin and fructosamine con-
centrations in DM and HSDM cats. P-values of <.05 were consid-
ered statistically significant. GraphPad Software was used.d
Results
Ghrelin Assay—Analytical Performance
Linearity under serial dilution of feline samples was
demonstrated with linear regression equations showing
a correlation coefficient approximating 1.0 (Fig 1A).
The mean recovery when mixing feline samples with
high and low ghrelin concentration was 96.4  6.9%
(range 86–103%) (Fig 1B). The assay LoD was 0.64 ng/
mL (mean 0.22  0.14 ng/mL) and values below this
were considered to be zero.
Mean intra-CV was 8.7%, 5.1%, and 11.2% for sam-
ples with low (4.3 ng/mL), medium (5.4 ng/mL), and
high (14.1 ng/mL) ghrelin concentrations, respectively,
and inter-CV was 7.8%, 8.3%, and 9.1% for a sample
with low (3.2 ng/mL), medium (6.7 ng/mL) and high
(10.2 ng/mL) ghrelin concentration, respectively.
Assessed Population
Mean body weight was significantly different between
the three groups (P < .001). Mean body weight was not
significantly different between the DM-cats and control
cats, though the bodyweight of HSDM-cats was signifi-
cantly higher than both other groups (P < .05; posthoc
Tukey’s multiple comparison test) (Table 1). The med-
ian insulin dose/kg in the HSDM-group was signifi-
cantly higher when compared to the DM group
(P < .001, Mann-Whitney U-test). For the subgroup of
HSDM-cats that underwent RT (HSDM+RT), median
insulin dose and mean serum fructosamine concentra-
tions were both significantly lower after RT when com-
pared to pretreatment values (insulin: paired-sample
Wilcoxon signed rank test, P = .01; fructosamine:
paired t-test, P = .02). The mean serum IGF-1 concen-
tration for the HSDM+RT-cats was not significantly
lower after RT (paired t-test, P = .24). Insulin dose,
IGF-1, fructosamine and ghrelin concentrations for the
group of HSDM-cats that underwent RT are illustrated
in Fig 2.
Feline Ghrelin Concentrations in DM-, HSDM-, and
Control-Cats
The mean  SD serum concentration of total ghrelin in
the HSDM-cats was 7.9  3.3 ng/mL (range 1.7–18.3 ng/
mL). The mean  SD total ghrelin concentration in the
DM-cats was 6.7  2.3 ng/mL (range 3.6–12.7 ng/mL),
whereas the mean total ghrelin in the control-cats was
12.9  6.8 ng/mL (range 2.4–32.3 ng/mL). Total ghrelin
concentration was significantly different between groups
(ANOVA, P < .001) and posthoc Tukey’s analysis identi-
fied that control cats had a significantly higher total
ghrelin concentration compared to HSDM and DM cats
(Fig 3).
The subpopulation of HSDM-cats that underwent
RT had a mean  SD pretreatment serum ghrelin con-
centration of 6.6  1.8 ng/mL (range 4.2–10.2 ng/mL).
The after RT total ghrelin was 9.0  2.3 ng/mL (range
5.4–12.7 ng/mL), which was significantly higher (paired
t-test, P < .0008) (Fig 4). Total serum ghrelin in HSDM
pre-RT cats (P = .0028), though not in HSDM after
RT cats (P = .055), was significantly lower compared to
control cats (multiple t-tests with Bonferroni posthoc
significance level a = 0.025).
Changes in serum ghrelin before and after RT did
not significantly correlate with changes in insulin dose
pre- and after RT (Spearman: r = 0.36; P = .22),
changes in serum IGF-1 (Pearson: r = 0.16; P = .59) or
fructosamine (Pearson: r = 0.02; P = .94). Additionally,
there was no significant correlation between serum fruc-
tosamine and ghrelin in the DM-cats (Pearson:
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r = 0.08; P = .074) or HSDM-cats (Pearson: r =
0.12; P = .51).
Discussion
Serum ghrelin in cats with HSDM and cats with
uncomplicated or primary DM has not previously been
studied. This study suggests that, in parallel to the situ-
ation in man,10–12,18,19 serum ghrelin is suppressed in
cats with HS-induced DM and in cats with DM unre-
lated to HS. Serum ghrelin is therefore not useful as a
diagnostic for determining the presence or absence of
HS in the diabetic cat. However, it might prove useful
as a marker for treatment effect, since serum ghrelin
increased to normal following RT in cats with HSDM.
The overlapping ranges of the ghrelin concentrations
in the before and after RT group might indicate a limi-
tation to the use of ghrelin as an indicator for treatment
effect and is also encountered in human acromegaly.20
Nevertheless, of all 13 assessed cats undergoing RT, 12
(92%) showed an increase in serum ghrelin, and in 11/
12 this was of a magnitude greater than the detection
limit of the assay. The rise in ghrelin concentrations
was accompanied by improved glycemic control
reflected by significant lowering of serum fructosamine
and insulin dose, indicating treatment effect. Interest-
ingly, serum IGF-1 concentrations were not significantly
changed after treatment, supporting current belief that
this represents a poor indicator of treatment effect when
it concerns RT for feline HS.8 Whether serum ghrelin
can actually predict a fall in insulin requirements has
yet to be determined and would require a future pro-
spective study with several sample time points after RT
before a decrease in insulin requirement. The latter will,
however, be a difficult study to perform, since the RT
effect might be seen 6 months to a year after treatment,
if it will take effect at all. In humans suffering from
acromegaly, IGF-1 concentrations attenuate very slowly
after RT and maximal control of the release of
GH may require more than 15 years. Radiotherapy is
therefore generally reserved for tumors that have
recurred or persisted after surgery.21 On the other hand,
successful hypophysectomy leads to an immediate
reduction in GH and IGF-1 and both parameters are
therefore used to assess biochemical control of disease,
as well as predict the risk of recurrence.22 This also
highlights the superiority of hypophysectomy over RT
in terms of HS-treatment efficacy in humans, rather
than a mere lack of sensitivity of IGF-1 after RT.
Feline case reports suggest this is also true for the hy-
persomatotropic cat.3,8,23,24
The diurnal variation in circulating ghrelin is a topic
of ongoing research in humans, with some conflicting
results in terms of influences on its secretion pattern.25
Whether there is diurnal variation in feline circulating
ghrelin concentrations is currently unknown. The rela-
tively small differences between before and after radia-
tion ghrelin concentrations could therefore also have
been confounded by such unknown natural ghrelin
dynamics. For instance, ghrelin is known to be influ-
enced by meals in man.26 Nevertheless, on 24-hour
serial assessment of circulating ghrelin concentrations in
humans, it was shown that samples taken before break-
fast correlated strongly with 24-hour integrated area
under the curve values (r = 0.873), suggesting that a sin-
gle starved morning sample could be used as a surro-
gate for 24-hour profiles to estimate overall ghrelin
concentrations.27 Therefore, to minimize the effects of
daily ghrelin dynamics in this study, all cat samples
were taken in the early morning and before food. Addi-
tionally, the reported amplitudes of ghrelin secretion
pulses in humans are usually in the range of
0.5  0.1 ng/mL,26 which therefore could only pose a
modest confounding factor, given that the difference
between the mean concentration of serum ghrelin before
and after radiotherapy in our cats was almost 5-fold
greater (2.4 ng/mL). Specific feline ghrelin physiology
research is nevertheless indicated to further evaluate
these issues, as well as an assessment of ghrelin stability
and ideal storage conditions.
Table 1. Physical characteristics, median (range) insulin dose and mean  SD serum fructosamine and IGF-1 con-
centrations of cats with diabetes mellitus (DM), cats with hypersomatotropism and diabetes mellitus (HSDM) includ-
ing the subgroup of cats that underwent RT (RT) and healthy age-matched control cats.
DM HSDM RT (Pre) RT (Post) Controls
Number (n) 20 32 13 13 20
Age (years) 12.1 (7–17) 10 (6–14) 10 (5–13) 11 (7–13) 11 (9–17)
Breed 19 DSH/1 Abysinian 29 DSH/2 DLH/1 BSH 11 DSH/1 DLH/1 BSH 18 DSH/1 DLH/1 BSH
Sex 12 MN/6 FN/2 FE 21 MN/9 FN/2 FE 9 MN/4 FN 12MN/8 FN
BW (kg) 3.9 (2.7–6) 5.5 (3.9–9.1)a 5.8 (3.9–9.1) 5.4 (3.9–10.1) 4.6 (2.1–5.8)
Insulin dose
(IU/kg/inj)
0.8 (0.2–1.) 2.7 (1–9.6)b 3.2 (1.4–9.6) 1.1 (0–4)c NA
Fructosamine
(lmol/L)
495  95 613  179b 623  157 475  174c NA
IGF-1
(ng/mL)
257  72 1562  381 1597  389 1412  387 NA
aSignificant difference compared to the DM- and control group (ANOVA; post-hoc Tukeys).
bSignificant difference compared to the DM-group (insulin: Mann-Whitney U-test/fructosamine unpaired t-test).
cSignificant difference compared to the before RT group (insulin: paired-sample Wilcoxon signed rank test; fructosamine: paired t-test).
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The ELISA used in this study evaluated total ghrelin
concentration, despite the existence of two major forms
of ghrelin in the body. The octanoylated or “active”
form of ghrelin known as acyl ghrelin can activate the
GH secretagogue receptor.9 The major form in blood is
the nonoctanoylated or “inactive” form known as desa-
cyl ghrelin. Nevertheless, increasing numbers of studies
report also biological effects of desacyl ghrelin and
studies in humans have shown that both forms are sup-
pressed in acromegaly, justifying the use of a total ghre-
lin ELISA.11,28,29 The study employed, after approriate
validation, a Rat/Mouse Ghrelin ELISA for measuring
feline ghrelin. The absence of commercially available
(recombinant) feline ghrelin posed a limitation in the
assessment of accuracy. Nevertheless, the choice of the
used ELISA system was based on its previous use for
this purpose16 and the fact that ghrelin has a highly
conserved amino acid sequence across species. Only one
amino acid difference exists between rat and feline ghre-
lin and synthetic rat ghrelin is able to stimulate GH
secretion in cats.15 This, in combination with the serial
dilution and spiking recovery data, obtained using mix-
tures of feline serum, suggests an adequate level of
accuracy of the chosen assay.
In humans, dogs and cats, the relationship between
endogenous ghrelin secretion and pituitary GH
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concentrations before and after RT for the 13 cats with HSDM
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Fig 3. Serum ghrelin concentrations in cats with hypersomatotro-
pism and diabetes mellitus (HSDM) (circles), cats with diabetes
mellitus (DM) (squares) and healthy control cats (triangles). Mean
values are indicated by long horizontal lines and standard devia-
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ence, P = .0028 (multiple t-tests; Bonferroni posthoc significance
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secretion is not fully elucidated.15,30–32 Humans with
acromegaly have lower ghrelin concentrations and these
tend to increase after surgery in correlation with nor-
malization of GH and IGF-I and improved insulin sen-
sitivity, suggesting negative feedback to occur exerted
by excess GH on ghrelin secretion.10,12,33 Based on the
before and after RT results of this study, this hypothe-
sized negative feedback effect could also be present in
the cat. The effect may be independent or could be con-
founded by changes in insulin secretion and sensitivity,
as well as glycemic control, induced by HS and its treat-
ment. Indeed, in humans, low ghrelin concentrations
have been associated with insulin resistance and devel-
opment of type 2 DM.14,18,28,34 In addition, hyperinsu-
linemia, acute hyperglycemia and poor long-term
glycemic control in cats with DM might impair ghrelin
secretion in humans.35,36 However, although in this
study the mean insulin dose and fructosamine concen-
tration for the HSDM+RT group were significantly
lower following RT, there was no significant correlation
between the changes in serum ghrelin concentration and
the changes in fructosamine or insulin dose. Addition-
ally, no correlations could be documented between fruc-
tosamine and ghrelin in the entire DM and HSDM cat
populations.
In order to prevent inclusion of hypersomatotropic
cats in the DM group, only cats with serum total IGF-1
concentration <700 ng/mL and modest insulin require-
ments with adequate diabetic control at time of sam-
pling were included. Additionally, these cats showed no
evidence of insulin resistance during a minimum of
6 months follow-up. At time of IGF-1 determination,
all cats had been diagnosed with DM and had been
started on exogenous insulin for a minimum of
1 month, making a false negative IGF-1 result, because
of the inhibitory effect of portal insulin deficiency on
hepatic IGF-1 production unlikely.37
Low fasting ghrelin concentrations have been consis-
tently associated with obesity independent of the pres-
ence of type 2 DM in people and negative feedback
from excess leptin produced by the numerous adipo-
cytes has been implicated in this process.38–42 In con-
trast, a previous study in obese and lean cats found
that fasting serum acylated ghrelin concentrations were
in fact slightly higher in an obese state (though the
mean difference was only 9 pg/mL).43 Nevertheless,
because of such possible impact of obesity or body con-
dition on ghrelin, the DM-group and control cats in
this study were weight-matched; additionally, none were
classified as obese by the attending clinician; further-
more, average body weight in these two groups was not
strongly suggestive of underdiagnosed obesity. Body
condition scores or DEXA scan results were unfortu-
nately not available for these two groups. The HSDM-
group cats were not weight-matched since weight gain
and a greater stature formed part of the pathogenesis of
the disease in many of this group, as evidenced by the
significantly higher body weights compared to the
DM- and control-cats. Nevertheless, the relationship
between ghrelin concentration and weight seen in the
human nonacromegaly population has been docu-
mented to be absent in human patients with acromeg-
aly.10 Additionally, body condition scores were
available for the feline HSDM group and did not indi-
cate presence of obesity in any of the 32 HSDM cats.
Body condition scores and weight did not significantly
change after RT in the assessed subpopulation of
HSDM cats undergoing this treatment, rendering it
unlikely that the detected significant increase in serum
ghrelin after RT was caused by a change in body condi-
tion or body fat.
In conclusion, the analytical performance of a rat and
mouse ghrelin ELISA was assessed to be appropriate in
the cat with satisfactory inter- and intra-assay precision,
linearity under dilution and recovery studies. This study
also suggests that in cats with HSDM and cats with DM
serum ghrelin is suppressed compared to healthy cats.
Serum ghrelin increased significantly following successful
RT in cats with HSDM to a level that was comparable to
control cats, highlighting the potential existence of a
direct or indirect negative feedback system between ghre-
lin and GH. Similar to the situation in human DM, the
role of ghrelin in feline DM remains to be elucidated.
Finally, further studies are necessary to investigate the
exact utility of serum ghrelin as a diagnostic tool to assess
RT effect in HSDM, whereas IGF-1 has been confirmed
to be insensitive for this purpose.
Footnotes
a The Peoples Dispensary for Sick Animals, Bow and Beaumont
Sainsbury Animal’s Hospital, Camden
b Ghrelin (Rat Mouse) EIA Kit (range 0–100 lg/mL), Phoenix
Pharmaceuticals Inc, Belmont, CA
c Bio-Tek EL808 8 channel absorbance reader, Potton, UK
d GraphPad Prism version 5.0a for Windows, GraphPad Software,
San Diego, CA
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